FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149731431> ?p ?o ?g. }

• W2149731431 endingPage "S122" @default.
• W2149731431 startingPage "S115" @default.
• W2149731431 abstract "In summary, the relative role of HCT versus prolonged TKIs is very uncertain in the pediatric and adolescent populations. The long-term effects of prolonged TKI usage appears to be lower than that seen with HCT, although only HCT can achieve a permanent remission. Any recommendation in children and adolescents is difficult to defend because of the lack of available clinical data. Based on the adult data and what little is known in children, a reasonable approach appears to be initial treatment with imatinib in children and adolescents with CML-CP, with a change to a second-generation TKI if there is an incomplete response or recurrence after an initial response. At the time of a change to the second-generation TKI, an allogeneic HCT from either a matched sibling or closely matched unrelated donor should be implemented. Monitoring recommendations of BCR-ABL for CML on TKI therapy or after HCT can at this time only be extrapolated from adult data with the caveat that these populations should be more closely monitored until additional data are obtained (Table 1). The long-term effects of TKI usage lasting for a number of decades represent a very big unknown factor as pediatric oncologists consider the most appropriate treatment for their patients with CML. We also conclude that randomized international trials are urgently needed to evaluate the best therapies for pediatric CML.Table 1Response Assessment, Warnings, Monitoring Intervals, and Interventions for CML Patients Treated with Imatinib and after SCT (see 16Suttorp M. Thiede C. Tauer J.T. Roettgers S. Sedlacek P. Harbott J. Chronic myeloid leukemia in pediatrics—first results from study CML-PAED II (ASH Annual Meeting abstract).Blood. 2009; 114: 145Google Scholar) Criteria for Response AssessmentTime Point∗During the first 2 years, monitoring should occur every 3 months. If a major molecular response (≤0.1%) is achieved, the monitoring interval may be prolonged. However, there are no pediatric data in support of this practice, and until further pediatric data are available, we recommend that peripheral blood be monitored for BCR-ABL every 3 months indefinitely.Insufficient Imatinib ResponseImatinib FailureWarningsMonitoring During TKI Therapy: At diagnosis——High-risk disease according to Sokal/Hasford risk scoreNot first chronic phase Add. cytogenetic abnormalities in Ph+ cells (Del 9q+) At 3 monthsLess than complete hematology responseNo hematologic response (stable disease or disease progression)Any new cytogentic abnormality in Ph+ or Ph− cells At 6 monthsLess than partial cytogenetic response (Ph+ >35%)No cytogenetic response (Ph+ >95%)Any new cytogenetic abnormality in Ph+ or Ph− cells At 12 monthsNo complete cytogenetic response (Ph+ >95%)No major cytogenetic response (Ph+ >35%)Any new cytogenetic abnormality in Ph+ or Ph− cells At 18 monthsLess than major molecular response (no 3 log reduction)No complete cytogenetic responseAny new cytogenetic abnormality in Ph+ or Ph− cells At any timeLoss of responseDisease progressionAny new cytogenetic abnormality in Ph+ or Ph− cellsMutation?Mutation?Intervention: SCT might be considered, depending on EBMT risk score at time of warning, insufficient response, or failure.Monitoring∗During the first 2 years, monitoring should occur every 3 months. If a major molecular response (≤0.1%) is achieved, the monitoring interval may be prolonged. However, there are no pediatric data in support of this practice, and until further pediatric data are available, we recommend that peripheral blood be monitored for BCR-ABL every 3 months indefinitely. post-SCT:Analysis of bone marrow aspirates by real-time quantitative RT-PCR at +1, +2, +3, +6, +9, +12 months after SCT; increase the assay frequency as needed.Definition of low-risk patient:1)Reduction of BCR-ABL mRNA levels by at least 2 log from baseline at 1 month post-SCT and continuous decline thereafter following SCT.2)Achievement of MMolR (ratio abl/bcr-abl ≤0.1%) and maintenance of this stable BCR-ABL transcript level post-SCT or continuous decline thereafter following SCT.3)Development of aGVHD grade II-IV or extensive cGVHD and Ph+ chromosome negative and stable or decreasing BCR-ABL transcript levels after SCT.4)CMolR (RT-PCR negative) after SCT.Intervention: No intervention for low-risk patients.Definition of high-risk patient:Not qualifying for any criteria of the low-risk group.Intervention: Based on individual decisions including withdrawal of immunosuppression, escalating donor lymphocyte infusions, and imatinib mesylate.SCT indicates stem cell transplantation; GVHD, graft-versus-host disease.∗ During the first 2 years, monitoring should occur every 3 months. If a major molecular response (≤0.1%) is achieved, the monitoring interval may be prolonged. However, there are no pediatric data in support of this practice, and until further pediatric data are available, we recommend that peripheral blood be monitored for BCR-ABL every 3 months indefinitely. Open table in a new tab" @default.
• W2149731431 created "2016-06-24" @default.
• W2149731431 creator A5022392635 @default.
• W2149731431 creator A5026879640 @default.
• W2149731431 creator A5043164298 @default.
• W2149731431 date "2011-01-01" @default.
• W2149731431 modified "2023-09-26" @default.
• W2149731431 title "Controversies in the Treatment of CML in Children and Adolescents: TKIs versus BMT?" @default.
• W2149731431 cites W1485790698 @default.
• W2149731431 cites W1968937358 @default.
• W2149731431 cites W1970595617 @default.
• W2149731431 cites W1972511503 @default.
• W2149731431 cites W1978269924 @default.
• W2149731431 cites W1995811536 @default.
• W2149731431 cites W1996544875 @default.
• W2149731431 cites W2010227622 @default.
• W2149731431 cites W2013426040 @default.
• W2149731431 cites W2015905880 @default.
• W2149731431 cites W2016953305 @default.
• W2149731431 cites W2018792615 @default.
• W2149731431 cites W2021648831 @default.
• W2149731431 cites W2032569611 @default.
• W2149731431 cites W2041548911 @default.
• W2149731431 cites W2042585013 @default.
• W2149731431 cites W2043271704 @default.
• W2149731431 cites W2048146061 @default.
• W2149731431 cites W2051693138 @default.
• W2149731431 cites W2051911643 @default.
• W2149731431 cites W2054984614 @default.
• W2149731431 cites W2063319055 @default.
• W2149731431 cites W2064704460 @default.
• W2149731431 cites W2072115506 @default.
• W2149731431 cites W2084452268 @default.
• W2149731431 cites W2090823852 @default.
• W2149731431 cites W2090896574 @default.
• W2149731431 cites W2097799776 @default.
• W2149731431 cites W2106628717 @default.
• W2149731431 cites W2107419121 @default.
• W2149731431 cites W2115162935 @default.
• W2149731431 cites W2142900411 @default.
• W2149731431 cites W2143939343 @default.
• W2149731431 cites W2147401383 @default.
• W2149731431 cites W2151029305 @default.
• W2149731431 cites W2166654361 @default.
• W2149731431 cites W2172231214 @default.
• W2149731431 cites W2275129310 @default.
• W2149731431 cites W2326165099 @default.
• W2149731431 cites W2531094580 @default.
• W2149731431 cites W2550585955 @default.
• W2149731431 cites W2551297326 @default.
• W2149731431 cites W2587039300 @default.
• W2149731431 cites W2593142701 @default.
• W2149731431 doi "https://doi.org/10.1016/j.bbmt.2010.09.003" @default.
• W2149731431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21195300" @default.
• W2149731431 hasPublicationYear "2011" @default.
• W2149731431 type Work @default.
• W2149731431 sameAs 2149731431 @default.
• W2149731431 citedByCount "35" @default.
• W2149731431 countsByYear W21497314312012 @default.
• W2149731431 countsByYear W21497314312013 @default.
• W2149731431 countsByYear W21497314312014 @default.
• W2149731431 countsByYear W21497314312015 @default.
• W2149731431 countsByYear W21497314312017 @default.
• W2149731431 countsByYear W21497314312018 @default.
• W2149731431 countsByYear W21497314312019 @default.
• W2149731431 countsByYear W21497314312020 @default.
• W2149731431 countsByYear W21497314312022 @default.
• W2149731431 countsByYear W21497314312023 @default.
• W2149731431 crossrefType "journal-article" @default.
• W2149731431 hasAuthorship W2149731431A5022392635 @default.
• W2149731431 hasAuthorship W2149731431A5026879640 @default.
• W2149731431 hasAuthorship W2149731431A5043164298 @default.
• W2149731431 hasBestOaLocation W21497314311 @default.
• W2149731431 hasConcept C118552586 @default.
• W2149731431 hasConcept C126322002 @default.
• W2149731431 hasConcept C187212893 @default.
• W2149731431 hasConcept C27415008 @default.
• W2149731431 hasConcept C2777583451 @default.
• W2149731431 hasConcept C2778729363 @default.
• W2149731431 hasConcept C3019892230 @default.
• W2149731431 hasConcept C71924100 @default.
• W2149731431 hasConceptScore W2149731431C118552586 @default.
• W2149731431 hasConceptScore W2149731431C126322002 @default.
• W2149731431 hasConceptScore W2149731431C187212893 @default.
• W2149731431 hasConceptScore W2149731431C27415008 @default.
• W2149731431 hasConceptScore W2149731431C2777583451 @default.
• W2149731431 hasConceptScore W2149731431C2778729363 @default.
• W2149731431 hasConceptScore W2149731431C3019892230 @default.
• W2149731431 hasConceptScore W2149731431C71924100 @default.
• W2149731431 hasIssue "1" @default.
• W2149731431 hasLocation W21497314311 @default.
• W2149731431 hasLocation W21497314312 @default.
• W2149731431 hasOpenAccess W2149731431 @default.
• W2149731431 hasPrimaryLocation W21497314311 @default.
• W2149731431 hasRelatedWork W1970442971 @default.
• W2149731431 hasRelatedWork W2002247001 @default.
• W2149731431 hasRelatedWork W2029308621 @default.
• W2149731431 hasRelatedWork W2053904016 @default.

• next